| Literature DB >> 31906391 |
Qinghua Cui1,2,3, Ruikun Du1,2,3, Miaomiao Liu1, Lijun Rong4.
Abstract
Lignans are widely produced by various plant species; they are a class of natural products that share structural similarity. They usually contain a core scaffold that is formed by two or more phenylpropanoid units. Lignans possess diverse pharmacological properties, including their antiviral activities that have been reported in recent years. This review discusses the distribution of lignans in nature according to their structural classification, and it provides a comprehensive summary of their antiviral activities. Among them, two types of antiviral lignans-podophyllotoxin and bicyclol, which are used to treat venereal warts and chronic hepatitis B (CHB) in clinical, serve as examples of using lignans for antivirals-are discussed in some detail. Prospects of lignans in antiviral drug discovery are also discussed.Entities:
Keywords: antivirals; drug development; lignans; mechanism
Mesh:
Substances:
Year: 2020 PMID: 31906391 PMCID: PMC6982783 DOI: 10.3390/molecules25010183
Source DB: PubMed Journal: Molecules ISSN: 1420-3049 Impact factor: 4.411
Figure 1The monomers and this classification of lignans.
The antiviral activities of lignans and their derivatives from plants.
| Subclass | Cpd | From Plants | Organs | Virus(es) | IC50 (μM) | CC50 (μM) | Status | MOA/Targets | Refs |
|---|---|---|---|---|---|---|---|---|---|
| Dibenzylbutanes | Niranthin | Whole plants | HBV | 15.6~25.1 | 369.9 In HepG 2.2.15 | In Vitro | inhibits DHBV DNA replication and HBV antigen expression. | [ | |
| NDGA | Leaves (resin) | DENV | No data | No data | In Vitro | targets genome replication and viral assembly | [ | ||
| HCV | 30 | 70 in Huh7 | NDGA-mediated alterations of host lipid metabolism, LD morphology, and VLDL transport affect HCV proliferation | ||||||
| WNV/ZIKV | 7.9/9.1 | 162.1 in Vero | WNV: disturb the lipid metabolism probably by interfering with the sterol regulatory element binding proteins (SREBP) pathway | ||||||
| IAV | In Vivo | suppresses replication of IAV and induction of cytokines, trypsin, and MMP-9, with improved animal survival | |||||||
| TMP | Leaves (resin) | WNV/ZIKV | 9.3/5.7 | 1071.0 in Vero | In Vitro | impaires viral replication | [ | ||
| poxvirus | No data | No data | In Vitro | prevents the efficient spread of virus particles from cell to cell | |||||
| HSV | 43.5 | 160 in Vero | In Vitro | TMP inhibits both these viruses replication by blocking the binding of the host cell transcription factor, Sp1, to viral promoters. | |||||
| HIV | 25 | No data | In Vitro | ||||||
| HPV | In Clinical | selectively interferes with HPV viral genes E6/E7 with Sp1dependent promoters, and induces apoptosis by inactivation of the CDC2/cyclin B complex (maturation promoting factor) and production and phosphorylation of survivin | |||||||
| Secoisolariciresinol dimethyleTher acetate | Air-dried aerial parts | HIV-1 | 5.27 | 11.6 | In Vitro | waiting for the deeper research | [ | ||
| Dibenzyltyrolactones | ATG | Whole plants | IAV | No data | No data | In Vitro | induce the production of interferon | [ | |
| HIV-1 | No data | No data | In Vitro | inhibit the expression of protein P17 and P24 of the HIV-1 virus | |||||
| Yatein | Dried leaves | HSV-1 | 30.6 ± 5.5 | >100 | In Vitro | inhibiting HSV-1 alpha gene expression, including expression of the ICP0 and ICP4 genes, and by arresting HSV-1 DNA synthesis and structural protein expression in HeLa cells | [ | ||
| Hinokinin | Woods | HBV | No data | No data | In Vitro | waiting for the deeper research | [ | ||
| HIV | <28 | 527 in H9 | |||||||
| SARS-CoV | >10 | >750 in Vero | |||||||
| HCMV | No data | 115 in A549 | |||||||
| Arylnaphthalenes | Diphyllin | genus | Epigeal part | ZIKV | 0.06 | 3.48 in MDCK | In Vitro | vacuolar ATPase (V-ATPase) inhibitors | [ |
| IAV | 0.1–0.6 in different strains | 24.1 in A549 | inhibit endosomal acidification, thus interfering with downstream virus replication | ||||||
| DGP | Stems and leaves | ZIKV | 0.01–0.07 | 15–32 | In Vitro | prevented the acidification of endosomal/lysosomal compartments in target cells, thus inhibiting ZIKV fusion with cellular membranes and infection. | [ | ||
| HIV-1 | 15–21 nM | No data | In Vitro | HIV-1 reverse transcription | |||||
| Aryltetralins | Roots and stems | Papilloma virus | Launched in China | waiting for the deeper research | [ | ||||
| Substituted tetrahydrofurans | lariciresinol-4- | Roots | IAV | 50 μg/mL | >200 μg/mL | In Vitro | pharmacological actions on the immune system, signal transduction, cell cycle, and metabolism | [ | |
| ( | HIV-1 | 0.66 mM | 0.67mM in C8166 | In Vitro | No report | [ | |||
| Isatindolignanoside A | CVB3 | 25.9 | >100 | In Vitro | waiting for the deeper research | [ | |||
| Clemastanin B | IAV | 0.087–0.72 mg/mL | 6.2–7.5 mg/mL | In Vitro | targets viral endocytosis, uncoating or RNP export from the nucleus | [ | |||
| 2,6-diarylfurofurans | Phillygenin | Fruits | IAV | In Vivo | reduce inflammation caused by IAV. | [ | |||
| Sesamin | Seeds | inflammatory cytokines induced by H1N1 | No data | No data | In Vitro | anti-inflammatory cytokines in human PBMCs | [ | ||
| Dibenzocyclooctene | Bicyclol | Analogue of schizandrin C from | HBV | Launched in China | inhibit virus replication in patients infected with HBV | [ | |||
| HCV | 30 | No data | In vitro/Vivo/Clinical | modulation of cytotoxic T lymphocytes | |||||
| Rubrifloralignan A | Fruits | HIV-1 | 40.46 | 123.35 | In Vitro | inhibit the early stage of HIV-1 replication | [ | ||
| 1,4-Benzodioxane lignans | Silymarin | Seeds | HCV | In Clinical | blocked HCV production, increased anti-inflammatory, anti-proliferative gene expressions without affecting serum albumin levels | [ | |||
| IAV | No data | No data | In Vitro | inhibition of late viral RNA synthesis | |||||
| Dimer of strebluslignanols | ( | Roots | HBV | 3.67/HBsAg 14.67/HBeAg | No data | In Vitro | inhibit the secretion of HBsAg and HBeAg | [ | |
| Secolignans | Peperomins A&B | Whole plants | HIV-1 IIIB | 5 | No data | In Vitro | related to the cytotoxicity expressed as CC50 of compounds | [ | |
IC50, inhibitory concentration of compound that produces 50% inhibition of virus-induced cytopathic effects; CC50, concentration that reduces the growth of target cells by 50%.
Figure 2Relationships between different classical lignans. It depicts the basic mother nucleus structure of different subtypes of classical lignans, the main structural feature of this subclass is the β-β′ linkage. Dibenzylbutane (central position) is the basic structure of classical lignan, other subtypes of lignans derive from this structure with different chemical reactions.
Figure 3Structures of dibenzylbutanes and corresponding compounds.
Figure 4Structures of dibenzylbutyrolactone and corresponding compounds.
Figure 5Structures of arylnaphthalene/aryltetralin and corresponding compounds.
Figure 6Structures of substituted tetrahydrofurans and corresponding compounds.
Figure 7Structures of 2,6-diarylfurofurans and corresponding compounds.
Figure 8Structures of dibenzocyclooctene and corresponding compounds.
Figure 9Bicyclol as an anti-HBV drug [76]. Schizandrin C was isolated from F. Schizandrae and verified as the most active compound in protection against liver injury in mice. DDB (Dimethyl dicarboxylate biphenyl) as an analog of schizandrin C has been widely used for the improvement of the abnormal liver function of CHB hepatitis in China. Bicyclol as a novel substitute for DDB was found to be more effective in protection against liver injury and was also showed to inhibit hepatitis virus replication in vitro and in vivo.
Figure 10Structures of some neolignan compounds.